ETF · Invesco
SBIX Invesco NASDAQ Biotech UCITS ETF
ISIN IE00BQ70R696London Stock Exchange: SBIXInvesco Ltd.
- Technology
- ETF
- ISA
- SIPP
- Accumulating
Latest close
LSE£56.33
on
- Ongoing charge
- 0.40% a year
- Fund size
- £273m
Source: TradingView, as of , at least 15 min delayed
At a glance
As of 30/09/2026, SBIX (Invesco NASDAQ Biotech UCITS ETF, ISIN IE00BQ70R696) closed at £56.33 on the London Stock Exchange. Its ongoing charge is 0.40% a year (about £40 on £10,000). Over the five years to 30/09/2026 its total return was +35.2%, or +5.7% after UK CPIH inflation.
Past returns
- 1 year to 30/09/2026
- +46.1%
- +41.5% after inflation (UK CPIH)
- 3 years to 30/09/2026
- +62.3%
- +46.4% after inflation (UK CPIH)
- 5 years to 30/09/2026
- +35.2%
- +5.7% after inflation (UK CPIH)
£1,000 put in five years ago would have been worth about £1,352 on 30/09/2026 — about £1,057 in today’s spending power, once price rises are taken out. Past performance is not a guide to future returns.
Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.
How we work it out:ReturnsReturns after inflationTotal returnReal returnCPIH
Calendar-year and 12-month returns
Calendar-year returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund): 2026 to 30/09/2026 +25.9%. Returns of Invesco NASDAQ Biotech UCITS ETF in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +53.3%.
| Year | Return | After inflation | Return shown as a bar |
|---|---|---|---|
| to | +25.9% | +22.4% |
| 12 months to | Return |
|---|---|
| from | +53.3% |
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , inflation: ONS CPIH
How we work it out:Calendar-year returnsWhat a calendar-year return isAccumulating and distributing
Risk: volatility and largest fall
Volatility (annualised)
18.8%over 1 year
Annualised from weekly returns. Higher means bumpier.
- Largest fall since August 2025
- −5.9%
- From to
- Below its highest weekly close since August 2025
- 0.0%
- High of , latest
In words: Volatility of Invesco NASDAQ Biotech UCITS ETF in pounds, annualised from weekly returns to 30/09/2026: 18.8% over 1 year. Largest fall in the price of Invesco NASDAQ Biotech UCITS ETF since August 2025, in pounds: −5.9% from 03/07/2026 to 31/07/2026. On 30/09/2026 the price of Invesco NASDAQ Biotech UCITS ETF was at its highest weekly close since August 2025, in pounds.
Source: Fundology, from recorded closes and the data vendor’s weekly price history, as of , price, with income reinvested in the fund
How we work it out:Risk figuresFallsVolatilityLargest fall
Charges compared with similar funds
- Ongoing charge
- 0.40%
- a year
- On £10,000
- £40
- a year, roughly
- Over five years
- £198
- of £10,000, before growth
- 33 charge less
- 11 the same
- 74 charge more
Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year, as of 01/10/2026: 74 of the 118 other technology funds charge more, 11 the same and 33 less (share classes counted once).
Source: Fund ongoing charges via TradingView, as of
A lower charge is not a promise of a higher return: what the fund holds matters more. Charges are the fund’s own published ongoing charges figure.
Read more:Ongoing charge (OCF)OCF and TERFee dragHow charges add up
In plain English
Invesco NASDAQ Biotech UCITS ETF is an exchange-traded fund (ETF) from Invesco, launched in 2014.
It tracks the NASDAQ / Biotechnology.
You buy and sell it through a share-dealing account or platform during stock-market hours, like a share.
Its ongoing charge is 0.4% a year — about £40 a year on every £10,000 invested, taken from the fund's value rather than billed to you.
Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
Technology: Software, chips, AI and other tech companies. One sector only, so prices can move more than a broad fund.
Terms:ETFIndex fundUCITSAccumulating or incomeShare classISIN
Key facts
- Ticker
- SBIX
- ISIN
- IE00BQ70R696
- Provider
- Invesco
- Tracks
- NASDAQ / Biotechnology
- Structure
- ETF
- An exchange-traded fund: bought and sold on the stock exchange through the day, like a share.
- Income
- Accumulating
- Income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
- Ongoing charge
- 0.40% a year · about £40 on £10,000
- Fund size
- £273m
- Launched
- Domicile
- Ireland
- Can be held in
- ISA and SIPP
- Currency hedged
- No
- Price currency
- Pounds (GBP)
- Category
- Technology
Price chart
Since 06/08/2026, the closing price went from £51.50 on 06/08/2026 to £56.33 on 30/09/2026 (+9.4%). The lowest close shown was £51.50 on 06/08/2026 and the highest £56.33 on 30/09/2026.
Chart: closing prices we have recorded since 06/08/2026.
Source: TradingView, as of , at least 15 min delayed
Five years of prices, and after inflation
8 weekly closes, from 06/08/2026 to 30/09/2026. The same history in September 2026 pounds, adjusted with ONS CPIH inflation.
Create a free account to see the 5-year price chart and the after-inflation chart
Sign-up takes an email address. There is no card to enter and nothing to pay.
How we work it out:Prices and returnsNAV and price
What it holds
Top 10 holdings
| Rank# | Holding | Weight as a percentage of the fund |
|---|---|---|
| 1 | Gilead Sciences | 8.16% |
| 2 | Amgen | 7.85% |
| 3 | Vertex Pharmaceuticals | 7.69% |
| 4 | Moderna | 5.04% |
| 5 | Regeneron PharmaceuticalsREGN | 5.03% |
| 6 | Revolution Medicines | 2.88% |
| 7 | Illumina | 2.71% |
| 8 | Biogen | 2.19% |
| 9 | Alnylam Pharmaceuticals | 2.16% |
| 10 | Roivant Sciences | 1.73% |
Source: Invesco, holdings as published, as of , company pages by TradingView
Where it invests
The portfolio by sector, country and type of asset, as a share of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed.
By sector
- Information Technology34.4%
- Health Care15.0%
- Financials13.2%
- Consumer Discretionary12.9%
- Industrials9.1%
- Communication Services5.5%
- Materials3.2%
- Energy2.8%
- Other sectors3.9%
By country
- United States87.6%
- Switzerland5.6%
- South Korea1.3%
- Netherlands1.1%
- Mexico1.0%
- Brazil0.9%
- Sweden0.9%
- Israel0.4%
- Other countries1.1%
244 holdings are listed for this fund. All 244 holdings of SBIX, with the full split by sector, country and type of asset.
All holdings
The fund publishes 244 holdings; the ten largest make up 45.4% of it.
Create a free account to see the full holdings list
Sign-up takes an email address. There is no card to enter and nothing to pay.
Holdings:Compare what it holds with another fundHoldings overlapHow overlap is measured
Funds tracking the same index
3 funds track NASDAQ / Biotechnology, this one included and share classes counted once; their ongoing charges range from 0.35% to 0.40% a year (30/09/2026).
| Fund | 1 year | 5 years |
|---|---|---|
| Invesco NASDAQ Biotech UCITS ETFThis fundAccumulating · 0.40% a year | +46.1% | +35.2% |
| iShares NASDAQ US Biotechnology UCITS ETFDistributing · 0.35% a year | +49.5% | +44.4% |
| iShares NASDAQ US Biotechnology UCITS ETFAccumulating · 0.35% a year | +50.0% | +45.9% |
Source: TradingView reported returns and fund ongoing charges, as of
Read more:Index fundsTracking differenceHow funds are compared
Risk and return in depth
Sharpe, Sortino and Calmar ratios
Sharpe, Sortino and Calmar ratios over 1 year, from weekly returns in pounds.
With a free accountLargest falls and recoveries
The 3 largest falls since August 2025, in pounds, with how many weeks each took to reach its low and to recover.
With a free account
Create a free account to see the risk ratios and each large fall and its recovery
Sign-up takes an email address. There is no card to enter and nothing to pay.
Rank among similar funds
Rank by total return over 1, 3 and 5 years among up to 11 technology funds investing in the US, not currency-hedged, highest first.
Pro
Pro — currently by invitation
Pro includes the rank among similar funds
Pro is open by invitation while it is being built. There is nothing to buy. To ask about access, email [email protected].
Questions people ask
What is the ongoing charge of SBIX?
The ongoing charge of SBIX is 0.40% a year — about £40 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Invesco NASDAQ Biotech UCITS ETF 0.40% a year, as of 01/10/2026: 74 of the 118 other technology funds charge more, 11 the same and 33 less (share classes counted once).
What does SBIX track?
SBIX tracks the NASDAQ / Biotechnology.
Is SBIX accumulating or distributing?
SBIX is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.
What is the ISIN of SBIX?
The ISIN of SBIX is IE00BQ70R696. An ISIN identifies one exact share class of a fund; SBIX is its ticker on the London Stock Exchange.
What were SBIX’s returns in each of the last five years?
Calendar-year returns of SBIX in pounds (price, with income reinvested in the fund): 2026 to 30/09/2026 +25.9%. Past performance is not a guide to future returns.
How has SBIX done after inflation?
Over the five years to 30/09/2026 SBIX’s total return was +35.2%, or +5.7% after UK CPIH inflation. Past performance is not a guide to future returns.
Similar funds
- IITUiShares S&P 500 Information Technology Sector UCITS ETF0.15% a year · £12bn
- XAIXXtrackers Artificial Intelligence & Big Data UCITS ETF0.35% a year · £5.4bn
- SMGBVanEck Semiconductor UCITS ETF Accum A USD0.35% a year · £5.4bn
- XXTWXtrackers MSCI World Information Technology UCITS ETF0.25% a year · £3.9bn
- SEMIiShares MSCI Global Semiconductors UCITS ETF AccumUSD0.35% a year · £3.7bn
- RBTXiShares Automation & Robotics UCITS ETF0.40% a year · £3.1bn
- ISPYCyber Security UCITS ETF0.73% a year · £2.3bn
- 0MVVAmundi MSCI World Information Technology UCITS ETF EUR ACC0.30% a year · £1.9bn
Sources and dates
- Prices
- London Stock Exchange closes via TradingView, at least 15 minutes delayed, latest
- Returns
- TradingView reported returns (net asset value with income reinvested where available)
- Calendar years, risk
- Fundology, from recorded closes (weekly history from the data vendor where our record is short)
- Inflation
- ONS CPIH, latest month used August 2026
- Charges
- The fund’s ongoing charges figure, via TradingView
- Holdings
- Invesco, as published,
- Identity
- FCA Financial Instruments Reference Data System (FIRDS) and the issuer
- Fund size
- TradingView, converted to pounds at the latest ECB reference rate
Methodology:Data sourcesReturnsCategoriesAll methods
A machine-readable copy of this page: Markdown.